MRI monitoring of tumor response following angiogenesis inhibition in an experimental human breast cancer model

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 30, Issue 3, 2003, Pages 448-455

  Turetschek, Karl ^a,b   Preda, Anda ^a   Floyd, Eugenia ^c   Shames, David M ^a   Novikov, Viktor ^a   Roberts, Timothy P L ^a   Wood, Jeanette M ^d   Fu, Yanjun ^a   Carter, Wayne O ^c   Brasch, Robert C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF VIENNA   (Austria)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Breast cancer; Contrast media; Magnetic resonance imaging; Vascular endothelial growth factor receptor tyrosine kinase

Indexed keywords

ANGIOGENESIS INHIBITOR; CONTRAST MEDIUM; GADOLINIUM PENTETATE ALBUMIN; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; PROTEIN TYROSINE KINASE INHIBITOR; SHU 555C; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG; VATALANIB;

ANGIOGENESIS; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER MODEL; CONTRAST ENHANCEMENT; CONTROLLED STUDY; FEMALE; HISTOLOGY; MICROVASCULATURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; RAT; TUMOR GROWTH;

EID: 12444325810     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-002-1000-5     Document Type: Article

References (43)

1. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992; 267: 10931-10934.
2. Mendel DB, Laird AD, Smolich BD, et al. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anti-Cancer Drug Design 2000; 15:29-41.
3. Fontanini G, Lucchi M, Vignati S, et al. Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. J Natl Cancer Inst 1997; 89:881-886.
4. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995;55:3964-3968.
5. Baker CH, Solorzano CC, Fidler IJ. Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. Cancer Res 2002; 62:1996-2003.
6. Brock CS, Lee SM. Anti-angiogenic strategies and vascular targeting in the treatment of lung cancer. Eur Respir J 2002; 19:557-570.
7. Cherrington JM, Strawn LM, Shawver LK. New paradigms for the treatment of cancer: the role of anti-angiogenesis agents. Adv Cancer Res 2000; 79:1-38.
8. Fujita M, Hayashi I, Yamashina S, Itoman M, Majima M. Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis. Biochem Biophys Res Commun 2002; 294:441-447.
9. Gutheil JC, Campbell TN, Pierce PR, et al. Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res 2000; 6:3056-3061.
10. Hoekman K. SU6668, a multitargeted angiogenesis inhibitor. Cancer J 2001; 7 Suppl 3:S134-S138.
11. Naglich JG, Jure-Kunkel M, Gupta E, et al. Inhibition of angiogenesis and metastasis in two murine models by the matrix metalloproteinase inhibitor, BMS-275291. Cancer Res 2001; 61:8480-8485.
12. Veikkola T, Karkkainen M, Claesson-Welsh L, Alitalo K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res 2000; 60:203-212.
13. Strawn LM, McMahon G, App H, et al. Flk-1 as a target for tumor growth inhibition. Cancer Res 1996; 56:3540-3545.
14. Gasparini G, Brooks PC, Biganzoli E, et al. Vascular integrin alpha(v)beta3: a new prognostic indicator in breast cancer. Clin Cancer Res 1998; 4:2625-2634.
15. Varner JA, Cheresh DA. Integrins and cancer. Curr Opin Cell Biol 1996; 8:724-730.
16. Pham CD, Roberts TPL, vanBruggen N, et al. Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor. Cancer Invest 1998; 16:225-230.
17. Wikstrom M, Moseley M, White D, et al. Comparison of Gd-DTPA and a macromolecular agent. Invest Radiol 1989; 24:609-615.
18. Shames DM, Kuwatsuru R, Vexler V, Muhler A, Brasch RC. Measurement of capillary permeability to macromolecules by dynamic magnetic resonance imaging - a quantitative noninvasive technique. Magn Reson Med 1993; 29:616-622.
19. White D, Wang S-C, Aicher K, Dupon J, Engelstad B, Brasch R. Albumin-(DTPA-Gd) 15-20: whole body clearance, and organ distribution of gadolinium. In: Society of Magnetic Resonance in Medicine, 8th Annual Meeting. Amsterdam, 1989.
20. Baxter AB, Melnikoff S, Stites DP, Brasch RC. Immunogenicity of gadolinium-based contrast agents for magnetic resonance imaging - induction and characterization of antibodies in animals. Invest Radiol 1991; 26:1035-1040.
21. Turetschek K, Huber S, Floyd E, et al. MRI characterization of microvessels in experimental breast tumors using a particulate contrast agent with histopathologic correlation. Radiology 2001; 218:562-569.
22. Ogan M, Schmiedl U, Moseley M, Grodd W, Paajenen H, Brasch RC. Albumin labeled with Gd-DTPA: An intravascular contrast enhancing agent for magnetic resonance blood pool imaging: preparation and characterization. Invest Radiology 1987; 22:665-671.
23. Wood JM, Bold G, Buchdunger E, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000; 60:2178-2189.
24. Daldrup H, Shames DM, Wendland M, et al. Correlation of dynamic contrast-enhanced MR imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media. AJR Am J Roentgenol 1998; 171:941-949.
25. Wedeking P, Sotak CH, Telser J, Kumar K, Chang CA, Tweedle MF. Quantitative dependence of MR signal intensity on tissue concentration of Gd(HP-DO3A) in the nephrectomized rat. Magn Reson Imaging 1992; 10:97-108.
26. Schwickert HC, Roberts TP, Shames DM, et al. Quantification of liver blood volume: comparison of ultra short TI inversion recovery echo planar imaging (ULSTIR-EPI), with dynamic 3D-gradient recalled echo imaging. Magn Reson Med 1995; 34:845-852.
27. Roberts TP. Physiologic measurements by contrast-enhanced MR imaging: expectations and limitations. J Magn Reson Imag 1997; 7:82-90.
28. Yano S, Herbst RS, Shinohara H, et al. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation. Clin Cancer Res 2000; 6:957-965.
29. Bruns CJ, Solorzano CC, Harbison MT, et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 2000; 60:2926-2935.
30. Roberts WG, Palade GE. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci 1995; 108:2369-2379.
31. Schwickert HC, Stiskal M, Roberts TP, et al. Contrast-enhanced MR imaging assessment of tumor capillary permeability: effect of irradiation on delivery of chemotherapy. Radiology 1996; 198:893-898.
32. Gossmann A, Okuhata Y, Shames DM, et al. Prostate cancer tumor grade differentiation with dynamic contrast-enhanced MR Imaging in the rat: comparison of macromolecular and small-molecular contrast media - preliminary experience. Radiology 1999; 213:265-272.
33. Helbich T, Roberts TPL, Rollins MD, et al. Non-invasive assessment of wound healing angiogenesis with contrast enhanced MRI. In: Contrast media research. Woodstock, Vermont, 1999.
34. Berthezene Y, Vexler V, Kuwatsuru R, et al. Differentiation of alveolitis and pulmonary fibrosis with a macromolecular Mr-imaging contrast agent. Radiology 1992; 185:97-103.
35. Saeed M, van Dijke CF, Mann JS, et al. Histologic confirmation of microvascular hyperpermeability to macromolecular MR contrast medium in reperfused myocardial infarction. J Magn Reson Imaging 1998; 8:561-567.
36. Berthezène Y, Mühler A, Lang P, et al. Safety aspects and pharmacokinetics of inhaled aerosolized gadolinium. J Magn Reson Imaging 1993; 3:125-130.
37. Aicher KP, Dupon JW, White DL, et al. Contrast-enhanced magnetic resonance imaging of tumor-bearing mice treated with human recombinant tumor necrosis factor-alpha. Cancer Res 1990; 50:7376-7381.
38. Engelbrecht MR, Saeed M, Wendland MF, Canet E, Oksendal AN, Higgins CB. Contrast-enhanced 3D-TOF MRA of peripheral vessels: intravascular versus extracellular MR contrast media. J Magn Reson Imaging 1998; 8:616-621.
39. Bremerich J, Roberts TPL, Wendland M, et al. Three-dimensional MR imaging of pulmonary vessels and parenchyma with NC100150 (Clariscan). J Magn Reson Imaging 2000; 11:622-628.
40. Weissleder R, Elizondo G, Wittenberg J, Rabito CA, Bengele HH, Josephson L. Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging. Radiology 1990; 175:489-493.
41. Weissleder R, Elizondo G, Wittenberg J, Lee AS, Josephson L, Brady TJ. Ultrasmall superparamagnetic iron oxide: an intravenous contrast agent for assessing lymph nodes with MR imaging. Radiology 1990; 175:494-498.
42. Donahue KM, Weisskoff RM, Chesler DA, et al. Improving MR quantification of regional blood volume with intravascular T1 contrast agents: accuracy, precision, and water exchange. Magn Reson Med 1996; 36:858-867.
43. Donahue KM, Weisskoff RM, Burstein D. Water diffusion and exchange as they influence contrast enhancement. J Magn Reson Imaging 1997; 7:102-110.